HomeInsights
INDUSTRY:
Pharma
TOPIC:
Products & Services, Manufacturers & Providers
TITLE:
IQWIG issues opinion on ticagrelor (Brilinta, AstraZeneca) for prevention after myocardial infarction
BRIEF:
According to the German Institute for Quality and Efficiency in Health Care (IQWIG), the added benefit was called into question by data subsequently submitted.
LEGAL IMPLICATIONS:
BUSINESS IMPLICATIONS:
